15,528 Shares in Natera, Inc. $NTRA Acquired by Corient Private Wealth LP

Corient Private Wealth LP bought a new position in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,528 shares of the medical research company’s stock, valued at approximately $4,215,000.

A number of other institutional investors and hedge funds have also bought and sold shares of NTRA. BlackRock Inc. purchased a new stake in shares of Natera in the 2nd quarter valued at $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in shares of Natera during the 2nd quarter valued at $5,117,000. Abbot Financial Management Inc. purchased a new position in Natera in the 2nd quarter worth $1,537,000. Eagle Health Investments LP purchased a new position in Natera in the 2nd quarter worth $4,302,000. Finally, Fifth Third Bancorp raised its position in Natera by 3,373.1% in the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock worth $2,251,000 after purchasing an additional 10,929 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider John Fesko sold 6,517 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider directly owned 197,257 shares in the company, valued at $63,424,043.21. The trade was a 3.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This represents a 64.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 103,472 shares of company stock worth $24,960,134 over the last quarter. 5.05% of the stock is owned by insiders.

Natera Price Performance

Shares of NASDAQ NTRA opened at $321.96 on Tuesday. The firm has a 50-day moving average of $286.93 and a 200 day moving average of $234.55. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $343.18. The stock has a market cap of $46.41 billion, a P/E ratio of -236.73 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the business posted ($0.74) EPS. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. Research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the subject of several analyst reports. Piper Sandler upped their price target on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. UBS Group set a $260.00 price objective on Natera in a report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Royal Bank Of Canada upped their price target on shares of Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein assumed coverage on Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $319.38.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.